Literature DB >> 23575729

Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.

Zhongyu Zhu1, Ponraj Prabakaran, Weizao Chen, Christopher C Broder, Rui Gong, Dimiter S Dimitrov.   

Abstract

More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23575729      PMCID： PMC7090799          DOI： 10.1007/s12250-013-3313-x

Source DB:  PubMed          Journal:  Virol Sin        ISSN： 1995-820X            Impact factor:   4.327


  104 in total

1.  Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Authors:  Ramalakshmi Darbha; Sanjay Phogat; Aran F Labrijn; Yuuei Shu; Yijun Gu; Michelle Andrykovitch; Mei-Yun Zhang; Ralph Pantophlet; Loic Martin; Claudio Vita; Dennis R Burton; Dimiter S Dimitrov; Xinhua Ji
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

2.  Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Kimberly A Bishop; Vidita Choudhry; Bruce A Mungall; Yan-Ru Feng; Anil Choudhary; Mei-Yun Zhang; Yang Feng; Lin-Fa Wang; Xiaodong Xiao; Bryan T Eaton; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  Monoclonal antibodies as innovative therapeutics.

Authors:  Janice M Reichert
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

Review 4.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

5.  Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold.

Authors:  Akiko Koide; John Wojcik; Ryan N Gilbreth; Robert J Hoey; Shohei Koide
Journal:  J Mol Biol       Date:  2011-12-16       Impact factor: 5.469

6.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

7.  Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.

Authors:  Rui Gong; Yanping Wang; Tianlei Ying; Dimiter S Dimitrov
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

Review 8.  Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Authors:  Melissa M Coughlin; Bellur S Prabhakar
Journal:  Rev Med Virol       Date:  2011-09-08       Impact factor: 6.989

9.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

10.  Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain.

Authors:  John E Pak; Chetna Sharon; Malathy Satkunarajah; Thierry C Auperin; Cheryl M Cameron; David J Kelvin; Jayaraman Seetharaman; Alan Cochrane; Francis A Plummer; Jody D Berry; James M Rini
Journal:  J Mol Biol       Date:  2009-03-24       Impact factor: 5.469
View more
  8 in total

Review 1.  A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Authors:  Christopher C Broder; Kai Xu; Dimitar B Nikolov; Zhongyu Zhu; Dimiter S Dimitrov; Deborah Middleton; Jackie Pallister; Thomas W Geisbert; Katharine N Bossart; Lin-Fa Wang
Journal:  Antiviral Res       Date:  2013-07-06       Impact factor: 5.970

2.  Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.

Authors:  Tianlei Ying; Lanying Du; Tina W Ju; Ponraj Prabakaran; Candy C Y Lau; Lu Lu; Qi Liu; Lili Wang; Yang Feng; Yanping Wang; Bo-Jian Zheng; Kwok-Yung Yuen; Shibo Jiang; Dimiter S Dimitrov
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

3.  N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance.

Authors:  Rui Gong; Yanping Wang; Tianlei Ying; Yang Feng; Emily Streaker; Ponraj Prabakaran; Dimiter S Dimitrov
Journal:  Mol Pharm       Date:  2013-05-29       Impact factor: 4.939

4.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

5.  G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity.

Authors:  Kasumi Tatsumi; Gyosuke Sakashita; Yuko Nariai; Kosuke Okazaki; Hiroaki Kato; Eiji Obayashi; Hisashi Yoshida; Kanako Sugiyama; Sam-Yong Park; Joji Sekine; Takeshi Urano
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

Review 6.  Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.

Authors:  Chunpeng Yang; Xinyu Gao; Rui Gong
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

Review 7.  Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.

Authors:  Guangyu Zhou; Qi Zhao
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

8.  Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.

Authors:  Shaojuan Zhao; Huajun Zhang; Xinglou Yang; Haiwei Zhang; Ying Chen; Yancheng Zhan; Xiaoqing Zhang; Rendi Jiang; Meiqin Liu; Lan Liu; Li Chen; Wei Tang; Cheng Peng; Xiaoxiao Gao; Zhe Zhang; Zhengli Shi; Rui Gong
Journal:  Nat Commun       Date:  2021-08-09       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.